Figure 1 4 Metabolic disorders and IBD The prevalence of metabolic disorders, including DM2 and obesity, is increasingly rising in the IBD population
The medication works at the neurological level to reduce food-seeking behavior
Regular check-ins for habits, protein/fiber goals, and adjustments
BPC-157 is not FDA-approved and remains investigational, so it is framed here as general wellness support rather than a treatment for any injury or condition
however, as with any compounded medication, formulations may vary
Shepard Specialty Papers, Watertown, TN) in a climate and temperature-controlled room (72 2 F) on a 12 hr/12 hr light/dark cycle (lights on at 13:15)